The drug development tool offers an alternative, clinically meaningful endpoint in clinical trials that evaluate pharmacologic treatments for alcohol use disorder.
A Connecticut psychiatrist agreed to a $455K settlement after an investigation identified fraudulent Medicare claims and unsafe controlled substance prescribing practices, resulting in DEA sanctions and a 20-year exclusion from federal health programs.
With no new FDA-approved drugs for chronic wound debridement since 1965, MediWound's phase 3 trial tests EscharEx for venous leg ulcers in 216 patients.
FDA-cleared clinical trials will assess the safety, immunogenicity, and viability of genetically modified pig kidney transplants in patients with end-stage renal disease.
Key trial data and insights behind US Food and Drug Administration approvals of novel psychiatric drugs are shown, highlighting methods, demographics, and pivotal outcomes.
“You are instilling fear into folks who may defer care, who may go without care, whose children may not get the vaccines they need, who may not be able to get treatment for an ear infection or surgery."
"[Esketamine] is now available as a standalone treatment, meaning patients may experience improvements in depressive symptoms as early as 24 hours and at 28 days—without the need for daily oral antidepressants."